​

Verve Therapeutics Ownership | Who Owns Verve Therapeutics?

OverviewForecastRevenueFinancialsChart

Verve Therapeutics Ownership Summary

Verve Therapeutics is owned by 31.63% institutional investors, 5.29% insiders, and 63.09% retail investors. Alphabet is the largest institutional shareholder, holding 14.66% of VERV shares. ARK Genomic Revolution is the top mutual fund, with 2.92% of its assets in Verve Therapeutics shares.

VERV Ownership Benchmark

TypeName% Inst% Insiders% Retail
StockVerve Therapeutics31.63%5.29%63.09%
SectorHealthcare Stocks 57.39%9.93%32.68%
IndustryBiotech Stocks 68.48%9.65%21.87%

Institutional Shareholders

Top Institutional Shareholders by Total Shares

HolderShares% HoldingValue
Alphabet12.35M14.66%$69.65M
Blackrock funding, inc. /de7.53M8.93%$42.44M
Bvf inc/il6.90M8.20%$38.94M
Blackrock6.62M7.96%$32.31M
Vanguard group4.01M4.76%$22.60M
Casdin capital4.00M4.74%$22.54M
Millennium management3.92M4.65%$22.10M
Schonfeld strategic advisors3.79M4.50%$21.37M
State street3.35M4.03%$16.35M
Novo2.40M2.85%$13.54M

Top Institutional Shareholders by % of Total Assets

HolderShares% AssetsValue
Arch venture management2.01M4.92%$11.33M
Alphabet12.35M4.06%$69.65M
Casdin capital4.00M1.50%$22.54M
Bvf inc/il6.90M1.32%$38.94M
Acuta capital partners160.20K0.91%$903.53M
Novo2.40M0.82%$13.54M
Redmile group1.32M0.52%$7.43M
Palo alto investors lp575.82K0.50%$3.25M
Ecor1 capital1.25M0.27%$7.05M
Vestal point capital, lp645.00K0.22%$3.64M

Top Buyers

HolderShares% AssetsChange
Bvf inc/il6.90M1.32%6.25M
Point72 asset management1.39M0.02%1.39M
Schonfeld strategic advisors3.79M0.12%1.38M
Blackrock6.62M0.00%1.25M
Jacobs levy equity management905.82K0.02%905.82K

Top Sellers

HolderShares% AssetsChange
Ark investment management---2.94M
State street3.35M0.00%-1.75M
Jpmorgan chase417.54K0.00%-1.23M
Nikko asset management americas---1.12M
Sumitomo mitsui trust---1.12M

New Positions

HolderShares% AssetsChangeValue
Point72 asset management1.39M0.02%1.39M$7.86M
Jacobs levy equity management905.82K0.02%905.82K$4.42M
Susquehanna fundamental investments291.38K0.02%291.38K$1.64M
Norges bank78.19K0.00%78.19K$440.97K
Syon capital53.47K0.03%53.47K$301.56K

Sold Out

HolderChange
Financial gravity asset management-3.00
Nelson, van denburg & campbell wealth management group-11.00
Riggs asset managment-22.00
True wealth design-31.00
Hollencrest capital management-53.00

Institutional Ownership Trends

DateHoldingsChange %SharesChange %OwnershipChange %Increased PositionChange %Decreased PositionChange %
Dec 31, 202454-69.66%26,637,343-64.58%310.40%33-65.26%13-71.11%
Sep 30, 20241766.67%75,178,380-1.22%891.06%971.04%44-4.35%
Jun 30, 2024165-76,110,149-6.75%910.95%96-4.95%4615.00%
Mar 31, 20241652.48%81,620,7739.25%980.85%101-8.18%4060.00%
Dec 31, 202316113.38%74,711,87916.98%1071.05%11025.00%258.70%

Top Mutual Funds Shareholders

HolderShares% HoldingChange
ARK Genomic Revolution2.47M2.92%-340.12K
Vanguard Total Stock Mkt Idx Inv2.13M2.40%-
iShares Russell 2000 ETF1.87M2.10%-16.17K
SPDR® S&P Biotech ETF1.38M1.55%-14.77K
T. Rowe Price Small-Cap Value1.17M1.32%-
Vanguard Institutional Extnd Mkt Idx Tr1.02M1.15%1.76K
Nuveen Quant Small Cap Equity R6961.00K1.08%-
T. Rowe Price US Small-Cap Core Equity910.26K1.08%-41.87K
CREF Stock R1868.91K1.03%175.51K
Vanguard Small Cap Index850.11K1.00%2.01K

Recent Insider Transactions

DateNameRoleActivityValue
Apr 02, 2025Kathiresan Sekar Chief Executive OfficerSell$40.76K
Apr 02, 2025Nickerson Joan Chief Administrative OfficerSell$11.52K
Apr 02, 2025Ashe Andrew D. See RemarksSell$11.13K
Apr 02, 2025Politi Jason Chief Technical Ops. Off.Sell$13.43K
Apr 02, 2025Dorval Allison Chief Financial OfficerSell$13.90K

Insider Transactions Trends

DateBuySell
2025 Q2-6
2025 Q1--
2024 Q4-1
2024 Q211
2024 Q1--

VERV Ownership FAQ

Who Owns Verve Therapeutics?

Verve Therapeutics shareholders are primarily institutional investors at 31.63%, followed by 5.29% insiders and 63.08% retail investors. The average institutional ownership in Verve Therapeutics's industry, Biotech Stocks , is 68.48%, which Verve Therapeutics falls below.

Who owns the most shares of Verve Therapeutics?

Verve Therapeutics’s largest shareholders are Alphabet (12.35M shares, 14.66%), Blackrock funding, inc. /de (7.53M shares, 8.93%), and Bvf inc/il (6.9M shares, 8.20%). Together, they hold 31.79% of Verve Therapeutics’s total shares outstanding.

Does Blackrock own Verve Therapeutics?

Yes, BlackRock owns 7.96% of Verve Therapeutics, totaling 6.62M shares as of Jun 2024. This represents 0.00% of BlackRock's total assets, with a market value of 32.31M$. In the last quarter, BlackRock increased its holdings by 1.25M shares, a 23.20% change.

Who is Verve Therapeutics’s biggest shareholder by percentage of total assets invested?

Arch venture management is Verve Therapeutics’s biggest shareholder by percentage of total assets invested, with 4.92% of its assets in 2.01M Verve Therapeutics shares, valued at 11.33M$.

Who is the top mutual fund holder of Verve Therapeutics shares?

ARK Genomic Revolution is the top mutual fund holder of Verve Therapeutics shares, with 2.92% of its total shares outstanding invested in 2.47M Verve Therapeutics shares.

Try Tickergate Pro Free

Customize Everything. 100% Flexibility. Fast and Easy to Use (No code or Excel Needed)

  • Customize your own personal stocks lists, views and charts

  • Choose from hundreds of fields, up to 15 years of history

  • Conduct deep comparison analysis

  • Discover trending investment themes

  • Find your next best investment

  • Research stocks using tools